Clinical trial design, biomarkers and end points in metabolic and alcohol-related liver disease.
Diaz LA, Thiele M, Louvet A, Lee BP, Ajmera V, Tavaglione F, Hsu CL, Huang DQ, Pose E, Bataller R, McClain C, Mellinger J, Tincopa M, Mitchell MC, Ratziu V, Rinella ME, Sarin SK, Shah VH, Szabo G, Wong VW, Bansal MB, Leggio L, Kamath PS, Krag A, Sanyal AJ, Arrese M, Arab JP, Anstee QM, Mathurin P, Loomba R.
Diaz LA, et al.
Nat Rev Gastroenterol Hepatol. 2025 Dec;22(12):866-884. doi: 10.1038/s41575-025-01120-5. Epub 2025 Sep 26.
Nat Rev Gastroenterol Hepatol. 2025.
PMID: 41006824
Review.
Metabolic and alcohol-related liver disease (MetALD) is a newly defined entity within the spectrum of steatotic liver disease, characterized by the interplay of cardiometabolic risk factors and alcohol consumption. ...These advances will ultimately accelerate dru …
Metabolic and alcohol-related liver disease (MetALD) is a newly defined entity within the spectrum of steatotic liver disease, charac …